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Limitations to the application of molecularly targeted
cancer therapies are the inability to accurately match
patient with effective treatment and the absence of
a prompt readout of posttreatment response. Nonin-
vasive agents that rapidly report vascular endothelial
growth factor (VEGF) levels using positron emission
tomography (PET) have the potential to enhance
anti-angiogenesis therapies. Using phage display,
two distinct classes of peptides were identified that
bind to VEGF with nanomolar affinity and high selec-
tivity. Co-crystal structures of these different peptide
classes demonstrate that both bind to the receptor-
binding region of VEGF. 18F-radiolabelling of these
peptides facilitated the acquisition of PET images of
tumor VEGF levels in a HM7 xenograph model. The
images obtained from one 59-residue probe, 18F-Z-
3B, 2 hr postinjection are comparable to those
obtained with anti-VEGF antibody B20 72 hr postin-
jection. Furthermore, VEGF levels in growing SKOV3
tumors were followed using 18F-Z-3B as a PET probe
with VEGF levels increasing with tumor size.
INTRODUCTION
A promising development in health care is the movement toward
targeted therapies that focus treatment on specific biomarkers
associated with a particular pathology (van’t Veer and Bernards,
2008). Continued advancement in this area will depend on
improved diagnostic tools that facilitate not just the customiza-
tion of treatments for a specific disease, but also the ability to
assess the response to these treatments, an approach referred
to as evidenced medicine (Basu, 2010). These advances
ultimately depend on improved biological understanding of the
disease and the molecularly distinct subtypes involved. The
significant advances in the understanding of the role of vascular
endothelial growth factor (VEGF) in normal and diseased states
have made this family of growth factors important targets forChemistry & Biology 18,therapeutic intervention (Chung et al., 2010). VEGF is a specific
mitogen that regulates the formation of new blood vessels during
embryogenesis (vasculogenesis) and the sprouting of new blood
vessels from pre-existing ones (angiogenesis) (Ferrara and
Davis-Smyth, 1997). Anti-VEGF therapies are known to be effec-
tive in the treatment of wet macular degeneration (Heier et al.,
2006) and cancers such as metastatic colon carcinoma (Hurwitz
et al., 2004) and nonsmall cell lung cancer (Sandler et al., 2006),
with ongoing efforts underway to identify, expand and improve
therapeutic regimens. The levels of VEGF secreted by growing
tumor change rapidly in response to increasing hypoxia with
VEGF levels correlated with the onset of metastasis (Ferrara
and Davis-Smyth, 1997). Molecules that rapidly report tumor
VEGF levels in a noninvasive manner would be a valuable tool
for managing anti-angiogenesis therapies (Bailey, 2010; Dowlati
et al., 2008).
Positron emission tomography (PET) is a clinically used nonin-
vasive imaging technology. Performing PET with radiolabeled
antibodies (immunoPET) aspires to be a method of choice for
obtaining comprehensive analysis of target expression and
availability in vivo (van Dongen et al., 2007). The relatively slow
penetration of tracers based on full length antibodies requires
uptake periods of 3–6 days to achieve optimum tumor-to-back-
ground contrast and the VEGF level can rapidly change during
this time in preclinical models (van Dongen et al., 2007). There-
fore, an imaging agent based on a smaller scaffold with good
tissue permeability allowingmore frequent noninvasive sampling
of tumor VEGF is warranted. The necessary clearance rate and
tissue penetration requires low molecular weight peptides that
bind to VEGF with nanomolar affinity that can be modified to
give clear PET images using the widely available 18F-radionu-
clide. For example, numerous accounts were published on
in vivo imaging using HER2 specific Z-domain derived peptides
with very high tumor uptake values (Kramer-Marek et al., 2008;
Orlova et al., 2006). The levels of HER2 receptor in these models
are very high (200–1000 ng/mg), for comparison the VEGF
amount in the most common models are 100–500 times lower
than HER2 levels in a typical HER 3+ tumor and therefore repre-
sent a more difficult target for imaging.
VEGF exists as a symmetrical dimer that signals by dimerizing
tyrosine kinase receptors, kinase insert domain containing
receptor (KDR) or fms-like tyrosine kinase-1 (Flt-1), at two839–845, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 839
Figure 1. Sequences and VEGF Affinity of Peptides Obtained from Phage Display
(A and B) Dominant peptide sequences identified from the screen against VEGF with first-generation (A) mini-Z and (B) full-length Z-domain libraries.
(C) Tightest peptide binders identified from second-generation full-length Z-domain libraries, with randomized residues shown in red.
(D) Cartoon representation of the crystal structure of the mini-Z highlighting randomized residues shown as sticks and coloring the helices according to (A).
(E) Cartoon representation of the crystal structure of the Z-domain highlighting randomized residues shown as sticks and coloring the helices according to (B).
See also Figures S1 and S2.
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Imaging VEGF with 18F-Peptidesidentical binding sites located at the poles of the receptor
binding domains (Wiesmann et al., 1997). The receptor-binding
domain is the most facile binding region as VEGF neutralizing
antibodies (Muller et al., 1998), and phage derived peptides
bind at this location (Pan et al., 2002; Wiesmann et al., 1998).
The peptides derived from the earlier studies (Pan et al., 2002;
Wiesmann et al., 1998) are not sufficiently potent to function as
effective PET probes. In order to find more potent binders,
libraries of a preorganized scaffold were displayed on phage
and panned against VEGF. The three helix 58-residue Z-domain
of staphylococcal protein A was chosen based on positive
results mutating this sequence to recognize the extracellular
domain of HER2 (Orlova et al., 2006). Through stabilizing
mutations and the addition of a disulfide constraint the Z-domain
is reengineered into a two-helix 34-residue ‘‘mini-Z’’ version
that retains the parent’s affinity (Starovasnik et al., 1997). Both
scaffolds can be synthesized using standard solid phase
methods in good yield, allowing easy modification for PET
imaging applications. We elected to investigate both scaffolds
simultaneously by panning libraries displayed on the minor840 Chemistry & Biology 18, 839–845, July 29, 2011 ª2011 Elsevier Lcoat protein of M13 phage against VEGF109. Here we report on
the selection process, describe structural and biochemical char-
acterization of the peptides selected, compare and contrast the
image quality obtained from different peptides modified as PET
probes in a HM7 colorectal carcinoma xenograft model, and
utilize the most promising probe to investigate VEGF levels in
a SKOV-3 ovarian cancer xenograft model.
RESULTS
Phage Display
The choice of the nine residues to be randomized was based on
previous work reengineering the Z-domain in order to select
binders against HER2 (Orlova et al., 2006) (Figure 1). These resi-
dues were selected because they define a well organized
binding surface within the context of the Z-domain and mini-Z
scaffolds (see Structural Studies of VEGF in Complex with
Phage-Derived Peptides). Libraries were constructed using
standard protocols that contained >109 unique members (Sidhu
et al., 2007) (see Experimental Procedures).td All rights reserved
Figure 2. Structures of the Complex between VEGF and the
Z-Domain Peptides and VEGF and the Mini-Z Dimer Peptides
(A) Structure of VEGF:Z-domain complex (Protein Data Bank [PDB] code:
3S1K). The VEGF homodimer is rendered as a transparent surface with chains
V and W represented as cartoons colored magenta and blue respectively, the
Z-domain peptides are represented as a cartoon with chains A and B colored
yellow.
(B and C) Open book view of the binding interface between the VEGF dimer
and the Z-domain. The VEGF homodimer and the Z-domain are represented
as surfaces. Residue coloring symbolizes the extent to which the solvent
accessible surface area is buried by complex formation (25%–49%, yellow;
50%–75%, orange; >75%, red).
(D) Structure of the VEGF:mini-Z dimer complex. VEGF is rendered as in (A)
and the mini-Z peptides are represented as cartoon with chains A and B of the
Z-domain peptide colored green and cyan, respectively.
(E and F) Open book view of the binding interface between the VEGF dimer and
the min-Z dimer. The VEGF homodimer and the Z-domain are represented as
surfaces. (PDB-ID 3S1K and 3S1B, respectively).
See also Figures S2 and S3 and Table S1.
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Imaging VEGF with 18F-PeptidesAfter four rounds of selection with the mini-Z library against
VEGF109, >95% of the clones bound specifically to VEGF with
all clones having unique sequences. After six rounds of selec-
tion, clone Mini-Z-1 (FNKECLLRYKEAALDPNLNLYQRIAKIVSI
DDDC) dominated (Figure 1A), and proved to be the tightest
binder by phage ELISA (IC50  300 nM), with Kd = 40 nM as
determined by Octet analysis with the synthetic peptide (see
Figure S2A available online). The high affinity of the Mini-Z-1
peptide warranted investigation of its structural and PET imaging
properties.
After four rounds of selection with the Z-domain library against
VEGF109, two unique sequence families were found: Z-1 consist-
ing of 58-residue peptides that aligned with the sequence of the
original Z-domain; and a second family, Z-2, in which an extra
alanine residue was inserted at position 14. This mutation
occurred during the selection process because the original
library was constructed exclusively with 58 residue peptides
and no 59 residue clone is found when the Z-domain library is
sequenced. Both families were present after six rounds, and
analysis of the Z-1 clones by phage ELISA showed IC50 values
approaching the micromolar range (Figure 1). The Z-2 class
demonstrated consistently higher affinity for VEGF as deter-
mined by phage ELISA (Figure 1). The tightest binding clone
from phage ELISA Z-1-2 was confirmed in Octet assay (Kd =
38 nM) with the synthetic peptide (Figure S2B). This is sufficiently
potent for PET imaging so Z-1-2 was carried on for structural and
PET imaging studies. Phage ELISA assays assessed the selec-
tivity of the mini-Z-1 and Z-1-2 against a panel of targets with
neither mini-Z-1 or Z-1-2 showing significant affinity for the
extracellular domain of HER2 or IgG, the original targets of the
reengineered scaffolds (Figure S1).
Second generation Z-domain libraries explored the role of the
additional residue introduced at position 14. Two libraries were
constructed that mirrored the original Z-domain libraries but
position 14 was randomized to all 20 natural amino acids. Inter-
estingly, all the clones examined after four rounds of sorting
contained an alanine at this position, indicating the mutation
on phage had selected for the optimal residue. Affinities were
determined by competitive phage ELISA, with tightest binders
Z-3A, Z-3B, and Z-3C synthesized and Kd values of 121, 55,
and 41 nM, respectively, as determined by Octet assay using
synthetic peptides (Figure 1). As a control, affinities were
obtained by Octet assay for VEGF165 and peptide Z-3B and
yielded similar results (data not shown). In order to determine
total VEGF concentration in mouse xenograft models, the
probes should bind comparably to human and murine VEGF.
Octet analysis determined that all of the peptides used in PET
imaging study bound to both human and murine VEGF with
2-fold increase in potency for murine VEGF (data not shown).
Structural Studies of VEGF in Complex with
Phage-Derived Peptides
We determined the crystal structures of both the Z-1-2 and the
mini-Z-1 peptides bound to VEGF at 2.5 A˚ and 2.9 A˚ resolution,
respectively (see Table S1 for data collection and refinement
statistics). The structures revealed that both peptides bind at
the two poles of the VEGF homodimer (Figure 2). The overall
structure of VEGF does not change on complex formation, and
is similar to previously determined VEGF crystal structuresChemistry & Biology 18,(Muller et al., 1998; Wiesmann et al., 1997, 1998). The crystal
structure of the VEGF:Z-domain complex shows that the
Z-domain binds as a three-helix bundle, with two molecules of
the Z-domain binding per VEGF dimer. The structure of the
VEGF:mini-Z-1 complex revealed that the mini-Z-1 peptides
bind to VEGF as dimers with residues from helix-1 of one mini-
Z-1 monomer and residues from helix-2 of the other mini-Z-1
monomer forming the VEGF binding interface (Figure S3). The
intrachain disulfide bond between Cys5 on helix-1 and Cys34
on helix-2 was well defined by the 2.9 A˚ electron density. We
confirmed that the mini-Z-1 dimer is required for complex forma-
tion by mutagenesis of critical residues that are important for the
dimerization of mini-Z-1 monomers. We determined that resi-
dues that disrupt the mini-Z-1 dimerization interface also bind
to VEGF with diminished activity (Figures S2C and S2D). Both
the Z-domain and the mini-Z-1 peptides bind to similar locations
of the VEGF homodimer and exhibit a high level of surface
complementarity for VEGF (Figure 2). Please refer to the Supple-
mental Experimental Procedures for the description of the inter-
actions between VEGF and mini-Z-1.
There was not sufficient electron density to build the first six
residues (VDNKFN) and the last residue (K59) of the Z-domain
peptides, suggesting that these residues do not make significant
interactions in the crystal structure. The remainder of the
Z-domain exhibits electron density and demonstrates that the
VEGF binding face of the Z-domain is distributed across helix-1839–845, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 841
Figure 3. Imaging VEGF in HM7 and SKOV3 Xenografts
Positron emission tomography (PET) images (coronal slice) of mice bearing
HM7 xenograft at 2 weeks postimplantation and SKOV3 xenograft at 4 weeks
postimplantation obtained with 89Zr-B20 (left) and 18F-Z-3B (right). See also
Figures S4 and S5.
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Imaging VEGF with 18F-Peptidesand helix-2. The interaction of the A-chain and B-chain of the
Z-domain peptides with the VEGF dimer are equivalent with
minimal differences that are likely due to differences in the crystal
environment, and therefore, the crystal structure results will be
described using the A-chain of the Z-domain. Of the residues
randomized in the selection of Z-domain peptide, Asn11 and
His29 are involved in hydrogen bond interactions with residues
from both chains V and W of the VEGF dimer. The Nd2 atom of
Asn11 makes a hydrogen bond interaction with Oe1 of Gln79
of chain V and the Od1 atom of Asn11 interacts with the back-
bone NH atom of Met18 that is located in the first turn of helix
a1 of chain W. His29, located in helix-2 of the Z-domain, makes
important interactions with Tyr21 and Tyr25 that are located at
the C terminus of helix a1 of chain W. The Nd1 atom makes
a hydrogen bond interaction with the OH atom of Tyr21 whereas
the aromatic imidazole ring of His29 stacks on top of the phenol
of Tyr25. All the other residues randomized for the selection are
involved in complementary van der Waals interactions at the
interface between Z-domain helices 1 and 2 and the VEGF
dimer, in addition His10 is involved in an intrachain hydrogen
bond interaction with the Og atom of Ser41 that is located at
the N terminus of helix-3. Other interactions that are likely to
aid the binding of the Z-domain to VEGF include a salt bridge
interaction between the Od1 atom of Asp26, which is located
at the C terminus of helix-1 of the Z-domain, and the Nz atom
of Lys48 located on the b2 strand of chain V. The backbone
carbonyl of Ala18 at the N terminus of helix-2 is involved in
a hydrogen bond interaction with the Ne2 atom of Gln89, located
on the b6 strand of chain V.
Both the Z-domain and the mini-Z peptides bind to VEGF at
the receptor binding face that is located at the two poles of the
homodimer (Figure 2). The Z-domain and mini-Z bind almost
entirely across the receptor binding site of VEGF (Wiesmann
et al., 1997, 1998). A single Z-domain peptide contacts 14 resi-
dues of the VEGF homodimer, with six hydrogen bond interac-
tions and 744 A˚2 buried surface area. An interesting result from
the initial selections was the insertion of an Ala residue at position
14 of the Z-domain. The Ala14 insertion is located in helix-1 of the
Z-domain and the structure suggests it is important as a spacer
in helix-1 that shifts the register of the residues in the Z-domain
so that they make more optimal interactions with the VEGF
homodimer. The side chain of Ala14 is close to the VEGF binding
interface, with the Cb atom making favorable van der Waals
interactions with the side chain atoms of Met18 in the VEGF
dimer. This interaction likely explains why all peptides identified
in subsequent rounds of selection retain Ala in this position. Of
the other residues randomized in the selection, Asn11 makes
two critical interactions with both chains of the VEGF homo-
dimer, the importance of Asn11 is underscored by the results
from the selection where it was conserved through rounds of
selection. In contrast, although His29 side chain makes a
hydrogen bond interaction with Tyr21 of VEGF, this residue
was not strongly favored during selection.
PET Imaging Studies
The peptides were 18F-fluorinated by copper catalyzed 1,3-
dipolar cycloaddition of 1-[18F]fluoro-11-azido-3,6,9-trioxa un-
decane (18F-PEG4-N3) to 4-pentynoic acid attached to the N
terminus in 21%–45% radiochemical yields within 120 min (see842 Chemistry & Biology 18, 839–845, July 29, 2011 ª2011 Elsevier LSupplemental Experimental Procedures for details) (Gill et al.,
2009). A model of colorectal carcinoma based on the HM7 cell
line was used to evaluate the imaging capacity of both the
18F-peptides and 89Zr-radiolabeled anti-VEGF antibody B20
(Liang et al., 2006). This model is known to express relatively
high levels of VEGF and the tumor growth is VEGF-dependent.
Mice bearing HM7 xenografts on right hind thigh were imaged
at 2 weeks after tumor implantation with all tested peptides. In
order to minimize the effect of the tumor growth and maximize
the throughput, the imaging was performed within 3 consecutive
days using low number of animals (n = 1–3) for each peptide. The
120 min dynamic scans were acquired and the peptides were
ranked based on tumor uptake, tumor-to-blood and tumor-to-
muscle ratios calculated from uptake values summed over the
last 30 min of the dynamic scan (Figure S5). The biodistributions
of all peptides were similar andwere dominated by fast renal and
hepatobiliary clearance leading to high uptake in the bladder and
intestine. Despite the tumor uptake being only 0.5%–1.0% ID/g,
the fast clearance provided low nonspecific uptake in tissues
surrounding the tumor, which allowed visualization of the tumor
implanted on the right thigh (Figure S4). The uptake of all
peptides in the HM7 tumor xenograft was in the same range
but 18F-Z-3B provided the best tumor-to-blood and tumor-to-
muscle ratios (Figure S5). The tumor uptake of peptide 18F-Z-
3B was (0.85 ± 0.14 %ID/g, n = 3) with average tumor-to-blood
and tumor-to-muscle ratios equal to 2.2 and 5.6 reached within
2 hr postinjection. The peptide 18F-Z-3B was therefore chosen
for further studies.
Although the tumor uptake of 89Zr-radiolabeled anti-VEGF
antibody B20 was approximately eight times higher than tumor
uptake of 18F-Z-3B the tumors were clearly visualized by both
probes (Figure 3), and the tumor-to-blood and tumor-to-muscle
ratioswere roughly comparable inHM7 tumormodel, 2.3 for anti-
body 72 hr postinjection and 2.2 for peptide 2 hr postinjection.
The 18F-labeled mini-Z-1 peptide was cleared more rapidly
through the renal route than 18F-Z-3B (Figure S7). Concurrent
with this work Ren et al. reported a modified mini-Z (Ren et al.,
2009) with single digit nanomolar affinity to HER2, with the
68Ga-labeled two-helix peptide showing tumor uptake values
only 20% of the three helix Z-domain derived peptide (Orlova
et al., 2006). This trend is similar to what we observed with
our mini-Z and Z-domain peptides. In light of the superiority of
18F-Z-3B we focused our studies on this imaging agent.td All rights reserved
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Figure 4. Changes in VEGF Levels
(A and B) The uptake of 18F-Z-3B in SKOV3 xenograft was measured by (A) PET and (B) expression of hVEGF in SKOV3 xenografts was determined ex vivo at
2–5 weeks posttumor implantation.
(C) Correlation of hVEGF amount in the tumor with the uptake of 18F-Z-3B.
See also Figure S6 and S7.
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Imaging VEGF with 18F-PeptidesThe peptide 18F-Z-3B was used to monitor levels of VEGF in
the growing ovarian tumor model based on SKOV3 ovarian
cancer cell line. The tumor-to-blood ratios in this model are 2.7
for 89Zr-B20 antibody 72 hr postinjection and 1.4 for the peptide
18F-Z-3B 2 hr postinjection (Figure 3). The VEGF level is known to
increase with the tumor size and age as a response to increased
hypoxia (Hendriksen et al., 2009). The animals (n = 4–6 per group)
bearing SKOV3 tumors were imaged by 30 min static scan after
90 min of conscious uptake at weeks 2, 3, 4, and 5 postinocula-
tion. After imaging, the animals were sacrificed and the tumor
tissue was excised and weighted, and the levels of human-
VEGF (hVEGF) and murine-VEGF (mVEGF) were measured by
ELISA. The tumor uptake of 18F-Z-3Bwas significantly increased
at week 4 compared to weeks 2 and 3 (p = 0.004 and 0.005) and
remained elevated at week 5 (Figure 4A), which correlated with
the increase of hVEGF levels at week 4 compared to weeks 2
and 3 (Figure 4B). The tumors became more heterogeneous
presumably due to necrosis as reflected by larger standard devi-
ation at week 5 postinoculation. The tracer uptake in muscle
remained unchanged between weeks 2 and 5 (Figure 4A). The
levels of mVEGF were 200 times lower than levels hVEGF in
the tumor tissue and increased in parallel with levels of hVEGF
(Figure S6). The observed increase of the tumor uptake of
18F-Z-3B correlated (r = 0.60, p < 0.01) with the measured levels
of hVEGF (Figure 4C); however, the slope of the regression line is
low, and this limits the quantitative prediction of the hVEGF level
in the tumor. Hence, although qualitative analysis is feasible,
further optimization is needed to develop a reliable quantitative
diagnostic.
DISCUSSION
As a first step in developing peptide-based diagnostics that
rapidly and reliably monitor tumor VEGF levels, we have used
phage display to identify novel 34-residue two-helix and 59-
residue three-helix domain peptides based on the Z-domain of
protein A. In the case of the 59-residue peptide we discovered
that only peptides incorporating an extra alanine into helix 1
bound to VEGF with detectable affinity. Analysis of the crystal
structure of the complex between VEGF and the Z-domainChemistry & Biology 18,peptide suggests a change in helix register is responsible for
increased binding affinity over the 58-residue peptide. Another
unanticipated result is that dimerization of 34-residue mini-Z
peptide is required for VEGF recognition. The combinatorial
biology approach used in this study was crucial in the identifica-
tion of two new classes of VEGF binding peptides, pointing to the
utility of this approach for obtaining novel high affinity binding
scaffolds to important biological targets (Sidhu et al., 2003).
A limiting factor in the application of PET imaging as a method
to monitor therapeutic regiment is the lack of suitable probes
that monitor disease state in a clinically relevant time frame.
The importance of anti-angiogenesis therapies suggest that
monitoring tumor VEGF levels in real time will be a critical tool
for maximizing patient benefit. This study demonstrates that
peptides can be used to detect VEGF in animal models. The
PET images obtained with the 18F-labeled 34-residue mini-Z
peptides showed poor tissue penetration and rapid renal clear-
ance, which yielded tumor to tissue ratios insufficient for the
production of usable images. However, the 59-residue peptide,
Z-3B, when radio-labeled with 18F yields PET images of tumor
VEGF levels 2 hr postinjection that are comparable to those
obtained with 89Zr-radiolabeled anti-VEGF antibody 72 hr post-
injection. The 18F-labeled Z-3B is suitable for quantitative deter-
mination of local VEGF level, demonstrating that it is possible to
use peptide-based tracers to image VEGF levels in a widely
accepted whole animal cancer model. We feel this is an impor-
tant step in creating new diagnostics that will guide anti-angio-
genesis therapeutics by identifying the optimal dosing regiment
and drug combinations that achieve the best patient outcome.
Work to optimize the system to produce images that better
quantitate tumor VEGF levels is under way and will be reported
in due course. The further optimization shall include increasing
the binding affinity and avidity (Friedman et al., 2007) of the
peptide as well as optimizing its clearance and metabolism.
SIGNIFICANCE
The implementation of target-based therapy and evidence
based medicine require the development of sensitive diag-
nostics that allow physicians to assess patient response to839–845, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 843
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Imaging VEGF with 18F-Peptidestreatment and customize each individuals therapy accord-
ingly. An attractive diagnostic approach in cancer is the
use of positron emission tomography (PET) to obtain rapid
images of how tumors are responding to treatment. PET
probes for tumor metabolism and proliferation are already
in clinical use. Antibody based probe has been developed
to investigate tumor vascularization by targeting vascular
endothelial growth factor (VEGF). However, it is preferable
to obtain high quality images in a single clinical visit as
opposed to having to wait days between PET probe intro-
duction and the opportunity to obtain high contrast images
as required with antibody based probes. In addition to
convenience, the use of short half-life isotopes also reduces
the overall radiation burden, making repeat measurements
more attractive. In order to create probes that image VEGF
two classes of peptides derived from the Z-domain of
protein A were developed that selectively bound to VEGF
with nanomolar affinity, with recognition at the receptor
binding site as demonstrated by X-ray crystal structure anal-
ysis. The smaller 38-residue peptide binds to VEGF as
a dimer and did not yield images with contrast comparable
to those obtained with antibody based probes. However,
one 59-residue three helix 18F-labeled peptide produces
images 2 hr postinjection that are comparable to images
obtained 72 hr postinjection with an 89Zr-labeled anti-VEGF
antibody. These results are a proof of concept for rapidly
imaging tumors by binding to an angiogenesis factor, which
can potentially serve as reporters of the effects of anti-
angiogenesis therapies.EXPERIMENTAL PROCEDURES
Phage Panning and Analysis
N-terminal gene 3 minor coat protein-displayed peptide libraries (>109 unique
members) were constructed by previously described methods (Sidhu et al.,
2007). Randomization of desired positions was done using trinucleotide
chemistry that allowed incorporation of 17 natural amino acids (Cys, Pro,
and Gly were excluded). For second generation libraries, NNK degenerate
codons were used (N = A/G/C/T and K = G/C) to allow randomization with
all 20 natural amino acids (see Supplemental Experimental Procedures for
details of the selection, peptide synthesis, and Octet analysis).Peptide Synthesis
Peptide were synthesized on The Symphony (Protein Technologies). Standard
Fmoc chemistry was used for the syntheses and each amino acid was double
coupled using HBTU, O-Benzotriazole-N,N,N0,N0-tetramethyl-uronium-hexa-
fluorophosphate, as the peptide coupling reagent. The peptides were taken
off the instrument and cleaved manually with 95% trifluoroacetic acid, 2.5%
triisopropylsilane, and 2.5% water for 2 hr. All peptides with two cysteine resi-
dues were cyclized by adding concentrated iodide in acetic acid to the crude
peptide. The mixture was stirred for 5 min followed by addition of Zn dust to
quench the excess of iodide. The crude peptides were then filtered through
celite. The peptides were purified by preparative high performance liquid chro-
matography. Biotinylated peptides were synthesized as described above on
The Symphony. A linker was coupled to the peptide before biotinylation. On
removal from the instrument the peptide on resin was reacted with a solution
of Fmoc-6-aminohexanoic acid (three equivalents), HATU, (2-(7-Aza-1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate), (three
equivalents), and diisopropylethylamine (five equivalents) in DMF for 20 min.
The Fmoc protecting group was removed with 20% piperidine in DMF for
5 min. Biotin (three equivalents) was then coupled to the peptide in a solution
of DMF with a 1 M solution of N,N0-Diisopropylcarbodiimide in dichlorome-844 Chemistry & Biology 18, 839–845, July 29, 2011 ª2011 Elsevier Lthane (three equivalents) for 24 hr. The peptides were cleaved, cyclized, and
purified as described above.
Structural Analysis
Residues 8–109 of VEGF109 were expressed, refolded, and purified as previ-
ously described (Christinger et al., 1996) and buffer-exchanged into 20 mM
Tris, pH 7.5, 150 mM NaCl. Both Mini-Z-1 and Z-2 were synthesized by
solid-phase methods and acetylated at the N terminus. Both peptides were
dissolved in 20 mM Tris, pH 7.5, 150 mM NaCl, mixed with VEGF109 in a 3:1
molar ratio, after which the mixture was equilibrated on ice for 1.5 hr and
used in crystallization trials without further purification. The VEGF109 concen-
tration in final mixture was optimized to 6 mg/ml.
Crystallization screening of the VEGF109:Mini-Z-1 complex resulted in crys-
tals growing in 0.1 M NaOAc, 0.02 M CaCl2, MPD 30.0% v/v, pH 6.0. Crystals
were optimized by microseeding into hanging drops composed of a mixture of
2 ml complex and 2 ml reservoir solution (83 mM NaOAc, 17 mM CaCl2, MPD
25.0% v/v, pH 6.0). The crystals were cryoprotected, flash frozen in liquid
nitrogen and diffraction data were collected at ALS Beamline 5.0.2 . The
VEGF109:Z-2 complex crystals grew from 0.2 M KI, 0.1 M MES, PEG 4000
25.0% v/v, pH 6.5. The crystals were cryoprotected, flash frozen in liquid
nitrogen, and diffraction data collected at ALS Beamline 5.0.2.
Radiochemical Synthesis
18F-peptides were prepared according to a previously published procedure
(Gill et al., 2009). Synthetic details are given in the Supplemental Experimental
Procedures along with the preparation of the 89Zr-antiVEGF antibody.
Animal Models
NCRnudemice of 8–10weeks of agewere obtained from Taconic and athymic
nude mice 8–10 weeks of age were purchased from Harlan Sprague Dawley
(Livermore, CA). Mice were inoculated on the right thigh with 5 3 106
SKOV3 cells (NCR nude) or 3.5 3 106 HM7 cells (athymic nude) in 100 ml of
Hank’s buffered salt solution. The athymic nude mice were Animal care and
treatment followed protocols approved by Genentech Institutional Animal
Care and Use Committee that is accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care.
MicroPET Imaging
Mice were anesthetized with 3% sevoflurane to effect and injected intrave-
nously via the tail vein with 0.2–0.3 mCi of 18F-radiolabeled peptide in isotonic
solution or 0.1–0.2 mCi of 89Zr-radiolabeled mAb (100–130 mL). The PET
imaging was performed on an Inveon PET/CT scanner. Animals were placed
head-first, prone position on the scanner bed and static or dynamic scans
were acquired. For 18F-peptides, dynamic data were acquired for 0–120 min
posttracer injection; alternatively, 30 min static scan was performed after
90 min of conscious uptake period. For 89Zr-mAb, static 30 min data were
collected at day 5 posttracer injection. Body temperature was measured by
a rectal probe and maintained with warm air. Full-body iterative image recon-
structions were obtained using maximum a posteriori algorithm (MAP, hyper-
parameter b = 0.05) and corrected for signal attenuation using the tissue
density obtained from CT. Projections were created with ASIPro software
(Siemens Preclinical Solutions) and used to obtain quantitative activity levels
in each organ of interest using region-of-interest analysis. The animals were
sacrificed immediately after imaging and tumors were collected, weighed,
and subjected to analysis of VEGF levels.
VEGF Level Measurement
The ELISA for VEGF protein in tumor was performed as previously described
with minor modifications (Liang et al., 2006). Briefly, excised tumor was
homogenized in 500 ml RIPA buffer (Sigma) and, after centrifugation, superna-
tant was collected and measured for total protein concentration by BCA assay
(Pierce). For human-VEGF (hVEGF), a sandwich ELISA was performed using
mAb 3.5F8 as coat and biotinylated A4.6.1 as detection antibody. A standard
curve was generated using 1–128 pg/mL of hVEGF165. For murine-VEGF
(mVEGF), a goat anti-mVEGF antibody (R&D Systems) coat and biotinylated
goat anti-mVEGF detection antibody was used. A standard curve was gener-
ated using 1–128 pg/mL of mVEGF164 (R&D Systems). To account for variabletd All rights reserved
Chemistry & Biology
Imaging VEGF with 18F-Peptidesprotein extraction efficiency from tumor tissue, measured VEGF levels were
normalized to the total protein concentration.
Statistical Analysis
The plots were constructed with R software version 2.10.1 (R Foundation
for Statistical Computing, Vienna, Austria). Statistical significance was
determined using a two-tailed Student’s t test or analysis of variance and
p values < 0.05 were considered significant; data are presented as mean ±
standard deviation if not stated otherwise.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
doi:10.1016/j.chembiol.2011.05.011.
ACKNOWLEDGMENTS
The authors would like to thank Betty Li for help with cloning, Dev Sidhu and
Charlie Eigenbrot for helpful discussion, Jean-Michel Vernes for VEGF expres-
sion analysis, and the Genentech DNA synthesis group for providing oligonu-
cleotides. All authors are or have been employees of Genentech., Inc.
Received: March 9, 2011
Revised: April 26, 2011
Accepted: May 2, 2011
Published: July 28, 2011
REFERENCES
Bailey, R.C. (2010). Grand challenge commentary: informative diagnostics for
personalized medicine. Nat. Chem. Biol. 6, 857–859.
Basu, S. (2010). Personalized versus evidence-based medicine with PET-
based imaging. Nat. Rev. Clin. Oncol. 7, 665–668.
Christinger, H.W., Muller, Y.A., Berleau, L.T., Keyt, B.A., Cunningham, B.C.,
Ferrara, N., and de Vos, A.M. (1996). Crystallization of the receptor binding
domain of vascular endothelial growth factor. Proteins 26, 353–357.
Chung, A.S., Lee, J., and Ferrara, N. (2010). Targeting the tumour vasculature:
insights from physiological angiogenesis. Nat. Rev. Cancer 10, 505–514.
Dowlati, A., Gray, R., Sandler, A.B., Schiller, J.H., and Johnson, D.H. (2008).
Cell adhesion molecules, vascular endothelial growth factor, and basic fibro-
blast growth factor in patients with non-small cell lung cancer treated with
chemotherapy with or without bevacizumab—an Eastern Cooperative
Oncology Group Study. Clin. Cancer Res. 14, 1407–1412.
Ferrara, N., and Davis-Smyth, T. (1997). The biology of vascular endothelial
growth factor. Endocr. Rev. 18, 4–25.
Friedman, M., Nordberg, E., Ho¨ide´n-Guthenberg, I., Brismar, H., Adams, G.P.,
Nilsson, F.Y., Carlsson, J., and Sta˚hl, S. (2007). Phage display selection of
Affibody molecules with specific binding to the extracellular domain of the
epidermal growth factor receptor. Protein Eng. Des. Sel. 20, 189–199.
Gill, H.S., Tinianow, J.N., Ogasawara, A., Flores, J.E., Vanderbilt, A.N., Raab,
H., Scheer, J.M., Vandlen, R., Williams, S.P., and Marik, J. (2009). A modular
platform for the rapid site-specific radiolabeling of proteins with 18F exempli-
fied by quantitative positron emission tomography of human epidermal growth
factor receptor 2. J. Med. Chem. 52, 5816–5825.
Heier, J.S., Antoszyk, A.N., Pavan, P.R., Leff, S.R., Rosenfeld, P.J., Ciulla, T.A.,
Dreyer, R.F., Gentile, R.C., Sy, J.P., Hantsbarger, G., and Shams, N. (2006).
Ranibizumab for treatment of neovascular age-related macular degeneration:Chemistry & Biology 18,a phase I/II multicenter, controlled, multidose study. Ophthalmology 113,
633.e631–633.e634.
Hendriksen, E.M., Span, P.N., Schuuring, J., Peters, J.P., Sweep, F.C., van der
Kogel, A.J., and Bussink, J. (2009). Angiogenesis, hypoxia and VEGF expres-
sion during tumour growth in a human xenograft tumour model. Microvasc.
Res. 77, 96–103.
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J.,
Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004).
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic
colorectal cancer. N. Engl. J. Med. 350, 2335–2342.
Kramer-Marek, G., Kiesewetter, D.O., Martiniova, L., Jagoda, E., Lee, S.B.,
and Capala, J. (2008). [18F]FBEM-Z(HER2:342)-Affibody molecule—a new
molecular tracer for in vivo monitoring of HER2 expression by positron
emission tomography. Eur. J. Nucl. Med. Mol. Imaging 35, 1008–1018.
Liang, W.C., Wu, X., Peale, F.V., Lee, C.V., Meng, Y.G., Gutierrez, J., Fu, L.,
Malik, A.K., Gerber, H.P., Ferrara, N., and Fuh, G. (2006). Cross-species
vascular endothelial growth factor (VEGF)-blocking antibodies completely
inhibit the growth of human tumor xenografts and measure the contribution
of stromal VEGF. J. Biol. Chem. 281, 951–961.
Muller, Y.A., Chen, Y., Christinger, H.W., Li, B., Cunningham, B.C., Lowman,
H.B., and de Vos, A.M. (1998). VEGF and the Fab fragment of a humanized
neutralizing antibody: crystal structure of the complex at 2.4 A resolution
and mutational analysis of the interface. Structure 6, 1153–1167.
Orlova, A., Magnusson, M., Eriksson, T.L., Nilsson, M., Larsson, B., Ho¨ide´n-
Guthenberg, I., Widstro¨m, C., Carlsson, J., Tolmachev, V., Sta˚hl, S., and
Nilsson, F.Y. (2006). Tumor imaging using a picomolar affinity HER2 binding
Affibody molecule. Cancer Res. 66, 4339–4348.
Pan, B., Li, B., Russell, S.J., Tom, J.Y., Cochran, A.G., and Fairbrother, W.J.
(2002). Solution structure of a phage-derived peptide antagonist in complex
with vascular endothelial growth factor. J. Mol. Biol. 316, 769–787.
Ren, G., Zhang, R., Liu, Z., Webster, J.M., Miao, Z., Gambhir, S.S., Syud, F.A.,
and Cheng, Z. (2009). A 2-helix small protein labeled with 68Ga for PET imaging
of HER2 expression. J. Nucl. Med. 50, 1492–1499.
Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A.,
Lilenbaum, R., and Johnson, D.H. (2006). Paclitaxel-carboplatin alone or
with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355,
2542–2550.
Sidhu, S.S., Fairbrother, W.J., and Deshayes, K. (2003). Exploring protein-
protein interactions with phage display. ChemBioChem 4, 14–25.
Sidhu, S.S., Feld, B.K., and Weiss, G.A. (2007). M13 bacteriophage coat
proteins engineered for improved phage display. Methods Mol. Biol. 352,
205–219.
Starovasnik, M.A., Braisted, A.C., and Wells, J.A. (1997). Structural mimicry of
a native protein by a minimized binding domain. Proc. Natl. Acad. Sci. USA 94,
10080–10085.
van Dongen, G.A., Visser, G.W., Lub-de Hooge, M.N., de Vries, E.G., and Perk,
L.R. (2007). Immuno-PET: a navigator in monoclonal antibody development
and applications. Oncologist 12, 1379–1389.
van’t Veer, L.J., and Bernards, R. (2008). Enabling personalized cancer medi-
cine through analysis of gene-expression patterns. Nature 452, 564–570.
Wiesmann, C., Christinger, H.W., Cochran, A.G., Cunningham, B.C.,
Fairbrother, W.J., Keenan, C.J., Meng, G., and de Vos, A.M. (1998). Crystal
structure of the complex between VEGF and a receptor-blocking peptide.
Biochemistry 37, 17765–17772.
Wiesmann, C., Fuh, G., Christinger, H.W., Eigenbrot, C., Wells, J.A., and
de Vos, A.M. (1997). Crystal structure at 1.7 A resolution of VEGF in complex
with domain 2 of the Flt-1 receptor. Cell 91, 695–704.839–845, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 845
